EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Metronidazole Conjugates as Antimicrobial Agents

Erol Akgün iD, Melike Demirayak, Leyla Yurttaş iD, Ülkiye Dudu Gül iD, Şeref Demirayak iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Erol Akgün und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Metronidazole, Anti-Infective Agents, Antifungal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metronidazole (MTZ) is one of the oldest and still used anti‐infective nitroimidazole group drug. Although it is effective against anaerobic bacteria, protozoa, and parasites in clinical settings, it lacks efficacy against aerobic microorganisms. Due to its efficient molecular structure and synthetic usability due to the alcohol group in its framework, medicinal chemists aimed to reach new more effective molecules such as MTZ‐hybrids. In this study, 2‐[(benzimidazole/benzoxazole/benzothiazol‐2‐yl)thio]‐ N ‐[2‐(2‐methyl‐5‐nitro‐1 H ‐imidazol‐1‐yl)ethyl]acetamide ( 5a−5j ) derivatives were synthesized and their antimicrobial and antifungal effects on aerobic bacteria and Candida spp. were investigated. Notably, most of newly designed conjugates displayed higher potency than MTZ itself, especially against Gram‐positive strains. Furthermore, chlorinated heterocyclic moieties provided the strongest effects. Docking studies using E. coli nitroreductase (PDB: 1IDT) revealed potential interactions with the flavin mononucleotide (FMN) cofactor, suggesting that these hybrids may undergo nitro‐group reduction analogous to MTZ. Additionally, pharmacokinetic predictions indicated generally favorable profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetronidazoleAnti-Infective AgentsAntifungal AgentsMolecular Docking SimulationMicrobial Sensitivity TestsCandidaAnimalsEscherichia coliNitroreductasesStructure-Activity Relationship

Stichwörter der Autor:innen

FMNaerobic microorganismsmetronidazolenitroimidazole

Substanzen

MetronidazoleAnti-Infective AgentsNitroreductasesAntifungal Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Marmara University, İstanbul, Türkiye.
  • Department of Pharmaceutical Chemistry, Institute of Graduate Education, Anadolu University, Eskişehir, Türkiye.
  • İnci Dental Polyclinic, Eskişehir, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Türkiye.
  • Department of Bioengineering, Faculty of Engineering, Bilecik Şeyh Edebali University, Bilecik, Türkiye.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, İstanbul Okan University, İstanbul, Türkiye.

ORCID-Profile: Erol Akgün, Leyla Yurttaş, Ülkiye Dudu Gül, Şeref Demirayak

Zitieren

APA

Akgün, E., Demirayak, M., Yurttaş, L., Gül, Ü. D., & Demirayak, Ş. (2025). Novel Metronidazole Conjugates as Antimicrobial Agents. Drug Development Research. https://doi.org/10.1002/ddr.70114

Vancouver

Akgün E, Demirayak M, Yurttaş L, Gül ÜD, Demirayak Ş. Novel Metronidazole Conjugates as Antimicrobial Agents. Drug Development Research. 2025. doi:10.1002/ddr.70114

BibTeX
@article{Akgn2025,
  author = {Akgün, Erol and Demirayak, Melike and Yurttaş, Leyla and Gül, Ülkiye Dudu and Demirayak, Şeref},
  title = {Novel Metronidazole Conjugates as Antimicrobial Agents},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70114}
}
Kostenlos starten →